Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To characterize the dose response for tanezumab when administered by SC injection at an 8-weekly interval (2 injections) for moderate to severe chronic pain associated with (IC/PBS). To evaluate the safety and tolerability of tanezumab in the treatment of moderate to severe chronic pain associated with IC/PBS.
Inclusion criteria
- Chronic pain including the pain of interstitial cystitis/painful bladder syndrome